Home › Fabry Disease › NCT04252066

A Global Prospective Observational Study of Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding

Who can join

All ages · Women

Inclusion Criteria:

Female patients meeting the following criteria will be eligible for study enrollment:

1. Patients with Fabry disease who are pregnant and/or breastfeeding, whether or not they are exposed to migalastat
2. Able and willing to provide informed consent or assent, if applicable.
3. Able and willing to provide HCP contact information.

Exclusion Criteria:

None

About the study

This is a global prospective observational study of women with Fabry disease and their infants during pregnancy and/or breastfeeding. The study will evaluate outcomes of pregnancy and/or breastfeeding in women and infants exposed to migalastat.

What is being tested

• migalastat (drug)

Sponsor: Amicus Therapeutics · Participants: 20 · Started: Mar 18, 2025

Contact the study team

• Pregnancy Registry Call Center · Phone: 888-239-0758

Official record on ClinicalTrials.gov — NCT04252066

Locations in the U.S.

Conditions

• Fabry Disease

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.